B. Metzler seel. Sohn & Co. AG Invests $701,000 in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

B. Metzler seel. Sohn & Co. AG purchased a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,276 shares of the company’s stock, valued at approximately $701,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Rhumbline Advisers raised its position in shares of IDEAYA Biosciences by 0.5% in the 4th quarter. Rhumbline Advisers now owns 113,561 shares of the company’s stock valued at $2,919,000 after purchasing an additional 585 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in IDEAYA Biosciences by 44.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock valued at $72,000 after acquiring an additional 853 shares in the last quarter. Assetmark Inc. boosted its stake in IDEAYA Biosciences by 2.5% during the 4th quarter. Assetmark Inc. now owns 45,269 shares of the company’s stock valued at $1,163,000 after acquiring an additional 1,084 shares during the last quarter. R Squared Ltd acquired a new position in IDEAYA Biosciences during the 4th quarter worth $35,000. Finally, NEOS Investment Management LLC grew its holdings in IDEAYA Biosciences by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 16,066 shares of the company’s stock worth $413,000 after acquiring an additional 1,577 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Stephens reaffirmed an “overweight” rating and set a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Wedbush restated an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, IDEAYA Biosciences currently has an average rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Stock Down 5.5 %

IDEAYA Biosciences stock opened at $14.71 on Friday. The firm has a 50-day moving average price of $20.05 and a two-hundred day moving average price of $25.19. IDEAYA Biosciences, Inc. has a 52-week low of $14.40 and a 52-week high of $44.42. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -4.46 and a beta of 0.51.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. Research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.